MARKET WIREStock Titan • 1d ago
The last patient starts dosing in Tiziana (TLSA)’s Phase 2 Alzheimer’s trial.Stock Titan report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
Why TLSA Stock dropped -16.25% Today — RQD Quant Desk Flash
$0.67 -16.25% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.65
Tiziana Life Sciences Ltd. (TLSA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $101.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TLSA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TLSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.67 (-16.25% 1D, market cap $101.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TLSA ranks #311 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TLSA compare to IMUX and VTVT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLSA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMUX (Immunic Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M) and VTVT (vTv Therapeutics Inc. (Class A)) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $99.5M). Among the 5-stock peer group, TLSA leads on earnings multiple (N/A) while IMUX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TLSA?
▼
For Tiziana Life Sciences Ltd. (TLSA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #311 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.65 (-3.11%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLSA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY TLSA SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.9M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$1.09-7.3% Next Q
55
Q2 (-2Q)Grade C-$1.01-13.9% Next Q
52
Q3 (-1Q)Grade C-$0.87-23% Next Q
50
CurrentGrade D$0.67-5.9% Hist 90D α
47
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TLSA Turnaround Squeeze
While TLSA currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.99) and Max Pain ($0.70) forces dealer call-delta covering toward $2.05.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLSA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TLSA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TLSA Stock dropped -16.25% Today — RQD Quant Desk Flash
Tiziana Life Sciences Ltd. (TLSA) dropped -16.25% to $0.67, trading at 2% of its 52-week range ($0.76 – $1.95). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.76 – $1.95) with RSI-14 at 34.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.67 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $2.9M annual free cash flow.
Live TLSA Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumabYahoo Finance report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMoomoo • 1d ago
Tiziana Life Sciences | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]Moomoo report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 1d ago
Tiziana's experimental MS treatment meets main goals in mid-stage studymarketscreener.com report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), ScinaiBenzinga report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
Management and deal teams from Tiziana (TLSA) will attend a Toronto MS meeting October 21–23.Stock Titan report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKalkine Media • 2d ago
Tiziana Life Sciences Announces Positive Phase 2a INFORM-MS Trial Results for Intranasal ForalumabKalkine Media report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingKey • 2d ago
Top U.S. Stock Gainers: Biggest Price IncreasesTradingKey report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 1d ago
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisTrial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as compared to placebo a
MARKET WIREYahoo • 13d ago
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in TorontoBOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development cand
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLSA)
- ✓Walkthrough of TLSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TLSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.80%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.90H $0.90L $0.67C $0.67VOL 1.29M
RES: $1.25SUP: $0.66SMA50: $0.99SMA200: $1.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TLSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on TLSA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TLSA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLSA)
Health Care Rank #311 of 1015
⚔️ IMUX vs TLSA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TLSA vs. IMUX, VTVT, UNCY, PMVP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Tiziana Life Sciences Ltd. (TLSA) ranks #311 by composite RQD confidence (47/100, grade D) and #650 by equity capitalization ($101.8M). Within this direct 5-issuer industry benchmark cohort, TLSA leads on earnings valuation at N/A trailing P/E, while IMUX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TLSA currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TLSA
ACTIVE
Tiziana Life Sciences Ltd. | D | 47/100 | — | — | — | -16.25% | $101.8M | Benchmark Subject |
| IMUX Immunic Inc. | E | 33/100 | — | — | -35.0% | -2.26% | $102.5M | /imux-vs-tlsa → |
| VTVT vTv Therapeutics Inc. (Class A) | E | 24/100 | — | — | -35.0% | -4.05% | $99.5M | /vtvt-vs-tlsa → |
| UNCY Unicycive Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -6.68% | $104.2M | /uncy-vs-tlsa → |
| PMVP PMV Pharmaceuticals Inc. | D- | 42/100 | — | — | -35.0% | +4.58% | $98.9M | /pmvp-vs-tlsa → |
2. TLSA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTTiziana Life Sciences Ltd. (TLSA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $101.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. TLSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TLSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.67 (-16.25% 1D, market cap $101.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TLSA ranks #311 in composite RQD confidence.
How does TLSA compare to IMUX and VTVT in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLSA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMUX (Immunic Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M) and VTVT (vTv Therapeutics Inc. (Class A)) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $99.5M). Among the 5-stock peer group, TLSA leads on earnings multiple (N/A) while IMUX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TLSA?
For Tiziana Life Sciences Ltd. (TLSA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #311 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TLSA trading relative to its 50-day, 200-day, and 52-week technical levels?
TLSA last traded at $0.67 (-16.25% on volume of 2,852,515 shares), positioning the stock -32.32% below its 50-day simple moving average ($0.99) and -44.63% below its 200-day simple moving average ($1.21). Across its 52-week range of $0.76 to $1.95, TLSA sits at the 0.0% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.75).
ROARABLE RATING BRIEF • RQD 47/100 (D)
✓ SEC XBRL & RQD VERIFIED
TLSA — Tiziana Life Sciences Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Tiziana Life Sciences Ltd. (TLSA) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $0.67 (-16.25% 1D, market capitalization $101.8M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (4/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Tiziana Life Sciences Ltd. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations..1B.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.76 – $1.95 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TLSA carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can TLSA sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $1.95 52-week high?
- Key Question #3: How sensitive is TLSA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
TLSA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Tiziana Life Sciences Ltd. (TLSA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 1d ago
The last patient starts dosing in Tiziana (TLSA)’s Phase 2 Alzheimer’s trial. Stock Titan report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab Yahoo Finance report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
Tiziana Life Sciences | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] Moomoo report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 1d ago
Tiziana's experimental MS treatment meets main goals in mid-stage study marketscreener.com report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), Scinai Benzinga report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
Management and deal teams from Tiziana (TLSA) will attend a Toronto MS meeting October 21–23. Stock Titan report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kalkine Media • 2d ago
Tiziana Life Sciences Announces Positive Phase 2a INFORM-MS Trial Results for Intranasal Foralumab Kalkine Media report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingKey • 2d ago
Top U.S. Stock Gainers: Biggest Price Increases TradingKey report covering Tiziana Life Sciences Ltd. (TLSA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TLSA Bull vs. Bear Conversation Board — What's Your Call at $0.67?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TLSA 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $0.98 (+22.5%)
📌 Pinned Debate The balance-sheet pillar scores 13/20 with a Piotroski F-Score of 6/9 and Debt/Equity of 0.5, while the news feed reports multiple clin
Picked up a starter position in TLSA in my $100K Virtual Cash book at $0.80. The balance-sheet pillar scores 13/20 with a Piotroski F-Score of 6/9 and Debt/Equity of 0.5, while the news feed reports multiple clinical milestones.. Trading inside a $0.76–$1.95 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
VolSurface_Trader 🐂 BULL
@BearTrap_Alert Shorting a 4/20 institutional whale-flow stock at $0.80 is dangerous when funds are rotating into Health Care.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $0.64 (-20.0%)
Spot @ $0.80 Valuation & margin reality check on TLSA at $0.80 before chasing here
Fading this rally in TLSA at $0.80. Valuation & margin reality check on TLSA at $0.80 before chasing here. With a beta of 1.0 and the stock sitting at $0.80 (52-wk range $0.76–$1.95), the easy multiple expansion is already priced in.